Neurim Pharmaceuticals is dedicated to developing innovative treatments for central nervous system (CNS) disorders, focusing on conditions such as insomnia, Alzheimer's disease, and sleep apnea. The company employs a multi-targeted approach in its research and development, particularly with its lead product candidates like Piromelatine and GAL-475. Piromelatine is designed to address the complex needs of Alzheimer's patients by improving sleep quality and cognitive function through its unique mechanism of action that targets melatonin and serotonin receptors. This dual action is expected to enhance neurogenesis and cognitive performance while also regulating sleep patterns, which are often disrupted in Alzheimer's patients.

In addition to Piromelatine, Neurim is advancing GAL-475, a novel therapeutic agent aimed at treating sleep apnea syndromes. This compound has shown promise in preclinical studies by modulating peripheral chemoreception, thereby improving respiratory drive and reducing the frequency and severity of apnea events without disturbing sleep. Neurim's commitment to addressing unmet medical needs is further strengthened by its collaborations with academic institutions and research organizations, which enhance its ability to bring groundbreaking pharmaceuticals to market for patients suffering from debilitating CNS-related disorders.

Israel

Neurim Pharmaceuticals is a neuroscience drug discovery and development company creating drugs for brain restoration & reinforcement, focusing on the central nervous system.

With a proven track record of drug development and commercialization, Neurim’s first products, Circadin® and Slenyto® , are already in use in more than 40 countries across 5 continents.

Constantly expanding into additional therapeutic areas, the R&D pipeline comprises new products that address insomnia, Alzheimer’s dementia and sleep apnea.

Neurim Pharmaceuticals

Company Details